SAVOR-TIMI 53: Saxagliptin showed no cardiovascular benefit

The cardiovascular safety and efficacy of some hypoglycemic including saxagliptin (Onglyza), an inhibitor of dipeptidyl peptidase 4 (DPP-4), is not well established. 16492 patients were randomized diagnosed with type 2 diabetes with a history of cardiovascular events or high risk to receive saxagliptin or placebo. Other medications for diabetes, including hypoglycemic, were permitted. The combined<a href="https://solaci.org/en/2015/06/24/savor-timi-53-saxagliptin-showed-no-cardiovascular-benefit/" title="Read more" >...</a>

2nd-generation drug-eluting stents, results for “real” patients at two years

Original title: Clinical Outcome Following Stringent Discontinuation of Dual Anti-Platelet Therapy After 12 Months in Real-World Patients Treated With Second-Generation Zotarolimus-Eluting Resolute and Everolimus-Eluting Xience V Stents: Two-Year Follow-up of the Randomized TWENTE Trial. Reference: Keneth T, Hanim S, et al. J Am Coll Cardiol 2013. Article in press.   In recent years there have been new drug-eluting<a href="https://solaci.org/en/2015/06/02/2nd-generation-drug-eluting-stents-results-for-real-patients-at-two-years/" title="Read more" >...</a>

PCI vs. CABG in patients aged under 50 years

Original title: Comparison of 30-Day and 5-Year Outcomes of Percutaneous Coronary Intervention Versus Coronary Bypass Grafting in Patients Aged ≤50 Years.  Reference: Fausto Biancari, et al. Am J Cardiology Article in Press.   Coronary artery bypass grafting (CABG) is associated with better evolution than percutaneous coronary intervention (PCI), mainly due to left main and multiple vessels re<a href="https://solaci.org/en/2015/06/01/pci-vs-cabg-in-patients-aged-under-50-years/" title="Read more" >...</a>

Current hemodialysis patients show similar results for sirolimus-eluting and paclitaxel

Original title: Drug-eluting stents in patients on chronic haemodialysis: Paclitaxel-eluting stents vs. limus –eluting stents Reference: Gabriel l. Sardi, et al. Cardiovasc Revasc Med. 2014 Mar;15(2):86-91. End Stage Renal Disease (ESRD) including renal failure on hemodialysis is associated with coronary heart disease and diabetes with subsequent need for revascularization that in this special population has a high<a href="https://solaci.org/en/2015/06/01/current-hemodialysis-patients-show-similar-results-for-sirolimus-eluting-and-paclitaxel/" title="Read more" >...</a>

Validation of the Bleeding Academic Research Consortium

Reference: Circulation. 2012; 125:1424–143 Abstract: For many years all efforts applied to the optimization of percutaneous coronary intervention (PCI) were aimed specifically at reducing ischemic events risk through the advent of: 1) new devices (medicated stents), reducing restenosis rates, revascularization and 2) development of new drugs with a potent anti-platelet or anticoagulant such as clopidogrel or,<a href="https://solaci.org/en/2015/06/01/validation-of-the-bleeding-academic-research-consortium/" title="Read more" >...</a>

Angioplasty with stenting in ischemic stroke when thrombolytic agents won

Original title: A Controlled Trial of Revascularization in Acute Stroke. Reference: Martin Roubec et al. Radiology. 2012;Epub ahead of print. One of the most crucial forecast factors in patients undergoing acute ischemic stroke, stroke caused by a blockage in a brain artery, is the time window to recanalization.  Thrombolytic agents have been proved useful but not always achieve<a href="https://solaci.org/en/2015/06/01/angioplasty-with-stenting-in-ischemic-stroke-when-thrombolytic-agents-won/" title="Read more" >...</a>

TOTAL Trial: The Best on Manual Thrombectomy in AMI Patients

Original title: Randomized Trial of Primary PCI with or without Routine Manual Thrombectomy. Reference: S.S. Jolly et al. for the TOTAL Investigators. N Engl J Med. 2015 Apr 9;372(15):1389-98. Manual thrombectomy is a routine procedure with ST elevation AMI patients. This common practice proved to reduce mortality in the TAPAS study. However, the TASTE study did not observe<a href="https://solaci.org/en/2015/05/20/total-trial-the-best-on-manual-thrombectomy-in-ami-patients/" title="Read more" >...</a>

Everolimus eluting stent in total occlusions

Original title: Safety and Effectiveness of Everolimus-Eluting Stents in Chronic Total Coronary Occlusion Revascularization Results From the EXPERT CTO (Evaluation of the XIENCE Coronary Stent, Performance, and Technique in Chronic Total Occlusions) Multicenter Trial. Reference: David E. Kandzari et al. J Am Coll Cardiol Intv. 2015, on line before print. The aim of this study was to evaluate<a href="https://solaci.org/en/2015/04/30/everolimus-eluting-stent-in-total-occlusions/" title="Read more" >...</a>

Clinical presentation of restenosis in the three generations of DES

Original title: Clinical Presentation and Outcomes of Coronary In-Stent Restenosis Across 3-Stent Generations. Reference: Marco A. Magalhaes et al. Circ Cardiovasc Interv. 2014;7:00-00. Studies evaluating the clinical presentation of restenosis after implantation of bare metal stent showed that the recurrence of stenosis is not a benign complication as previously thought, with a significant number of patients with restenosis<a href="https://solaci.org/en/2015/04/28/clinical-presentation-of-restenosis-in-the-three-generations-of-des/" title="Read more" >...</a>

Angioplasty using a drug eluting balloon in the superficial femoral artery

Original title: Drug-Coated Balloon Versus Standard Percutaneous Transluminal Angioplasty for the Treatment of Superficial Femoral and Popliteal Peripheral Artery Disease 12-Month Results From the IN.PACT SFA Randomized Trial. Reference: Gunnar Tepe et al. Circulation. 2015;131:495-502. This interesting study randomly selected 331 patients with intermittent claudication or ischemic rest pain due to stenosis of the superficial femoral artery or<a href="https://solaci.org/en/2015/04/27/angioplasty-using-a-drug-eluting-balloon-in-the-superficial-femoral-artery/" title="Read more" >...</a>